Navigation Links
Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer

--Immunization with a Bavituximab Equivalent and Irradiated Tumor Cells Increased Long-Term Survival to 57% From 0% in Controls in a Preclinical Model of Brain Cancer--

LOS ANGELES and TUSTIN, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced preclinical studies presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that 2aG4, a mouse equivalent to the company's anti-phosphatidylserine (PS) antibody bavituximab has vaccine- like activity and can generate curative responses in an aggressive model of brain cancer. Researchers also presented data demonstrating that this improvement in survival was likely attributable to the ability of 2aG4 to enable the treated animals to mount an effective immune response against this difficult to treat cancer.

To confirm that the bavituximab equivalent 2aG4 acted by enhancing anti- cancer immune responses, researchers injected rats with irradiated glioma cells (inactivated tumor cells) along with 2aG4. This regimen was intended to protect the animals from a subsequent challenge with a large lethal dose of tumor cells -- 10,000 times the number required to produce lethal disease in this model.

Among the animals pre-treated with the 2aG4-treated irradiated cells, 57% achieved long-term survival, versus 0% of animals receiving no prior treatment (P < 0.01). The key role of the bavituximab equivalent's anti-PS activity in protecting these animals was illustrated by the fact that a group receiving irradiated control antibodies that did not block PS only achieved a 16% long- term survival rate.

These data are particularly noteworthy because the glioma cells used in the study are highly aggressive -- fewer than 10 cell
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:5/1/2015)... , May 01, 2015 Research and Markets ... the "US ACO IT Spending Outlook 2018" ... that number of lives covered by ACO would grow ... this report, the ACO IT spending has been studied ... on software and spending on services. Our research provides ...
(Date:5/1/2015)... May 1, 2015  Thoratec Corporation (NASDAQ: THOR ), ... support and restore failing hearts, announced today that Marta ... of President, International. This new Europe ... outside of North America , including ... Latin America , and reports directly to ...
(Date:5/1/2015)... Corporation (CYTR), a biopharmaceutical research and development company ... the three months ended March 31, 2015, and ... milestones for its clinical development programs. ... of 2015, including the announcement of encouraging data ... with soft tissue sarcoma, and positive interim data ...
Breaking Medicine Technology:United States ACO IT Spending Outlook 2014-2018 2Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11
... stimulants combined provide greater improvement in symptoms ... Addrenex Pharmaceuticals, Inc. today announced positive results ... Clonicel demonstrating that the combination of Clonicel ... in attention deficit hyperactivity disorder (ADHD) symptoms ...
... After a review of several vendors, the University ... selected the services of Velos and its flagship product, ... implemented at UCLA,s Jonsson Comprehensive Cancer Center and an ... Plans are in place to deploy the system in ...
Cached Medicine Technology:Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication 2University of California Los Angeles Selects Velos eResearch 2University of California Los Angeles Selects Velos eResearch 3University of California Los Angeles Selects Velos eResearch 4University of California Los Angeles Selects Velos eResearch 5University of California Los Angeles Selects Velos eResearch 6
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part of ... technology products available to consumers. Scott Steinberg, a technology expert ... with viewers how to protect their private information. , A ... and even more so online. It helps everyone stay connected ... world. In terms of work, the internet makes things more ...
(Date:5/3/2015)... MA (PRWEB) May 03, 2015 SpineFrontier, ... clearance from the FDA to produce and market their ... device can be used in outpatient settings and is ... The alternate posterior approach has been extensively researched and ... 510k approval to use this approach in conjunction with ...
(Date:5/2/2015)... As one of only 30 Illinois companies ... Health Achievement and Recognition Program (SHARP) certification, Essentra ... the Illinois Department of Labor to host this special ... certification by the Occupational Safety and Health Administration’s (“OSHA”) ... to meet or exceed all of the necessary regulations ...
(Date:5/2/2015)... “ ActOn ” was featured on NewsWatch ... at the latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... organizations to make a difference. , In this material world, ... that aren’t about money, which is why those things should ...
(Date:5/2/2015)... FL (PRWEB) May 02, 2015 We ... selected The Delray Recovery Center as one of the ... is known in the addiction treatment field for their ... members to innovate and to continue their educational efforts. ... positive workplace environment, never forgetting their purpose – to ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2
... screens, researchers say , TUESDAY, June 2 (HealthDay News) -- ... more types of cancer than previously thought, a new study ... successfully used for early detection of colorectal cancer, researchers at ... also good at finding other gastrointestinal cancers, such as those ...
... that a noninvasive screening test can detect not only colorectal ... including pancreas, stomach, biliary and esophageal cancers. This is one ... Digestive Disease Week 2009 in Chicago, May 30 June ... in four cancer deaths. While high cure rates can be ...
... New York, NY 2 June 2009 -- PharmaPendium ... clinical and post-marketing drug information, has significantly expanded its ... documents with the launch of the FDA Classic Collection. ... up to and including those issued in 1991 ...
... to use a new, cutting edge diagnostic technology to fight ... , WOBURN, Mass., and VEDBAEK, Denmark, June 2 ... Savannah, Georgia has implemented AdvanDx,s PNA FISH(R) tests to identify ... to help their physicians, pharmacists and nurses improve care and ...
... Pa., June 2 Globus Medical, Inc., the largest privately ... launch of the COALITION(TM) ACDF Spacer System. COALITION(TM) is ... biomechanical strength of a traditional ACDF with less disruption of ... , The COALITION(TM) technology combines a PEEK interbody spacer with ...
... Del., June 2 Two studies from ... gastroesophageal reflux disease (GERD) patients treated with NEXIUM(R) (esomeprazole ... heartburn and GERD-related sleep disturbances compared with patients taking ... for the treatment of heartburn and other symptoms associated ...
Cached Medicine News:Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 3Health News:Elsevier's PharmaPendium introduces the FDA Classic Collection 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:Globus Medical Announces Launch of COALITION(TM) ACDF Spacer System 2Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 2Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 3Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 4Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 5
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
Shandon Paraffin Block Cartons...
... embedment block cataloging and ... system incorporates the necessary ... protection, simplified cataloging, reduction ... facilitation of retrieval. All ...
The Modular Storage Drawers provide permanent storage and identification of up to 165 embedding rings or 250 cassettes per drawer....
Medicine Products: